Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-07 — Deep Dive: Hypertension in Chronic Kidney Disease

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-07 — Deep Dive: Hypertension in Chronic Kidney Disease
Tier: Tier 1 — Foundational Recall

1. A patient with CKD stage 3a and a UACR of 420 mg/g is started on an ACE inhibitor. Two weeks later, his serum creatinine has risen by 28% from baseline. His potassium is 4.9 mEq/L and he feels well. Which statement best describes the clinical significance of this creatinine rise?

A) It indicates early nephrotoxicity and the ACE inhibitor should be discontinued immediately.
B) It reflects excessive volume depletion; the ACE inhibitor dose should be halved and a diuretic added.
C) It is an expected hemodynamic response reflecting reduced intraglomerular pressure and is associated with long-term renoprotection.
D) It indicates that the ACE inhibitor has begun to reduce proteinuria effectively, and the creatinine rise will resolve within 48 hours.
E) It exceeds the acceptable threshold; the ACE inhibitor should be held and reinitiated at a lower dose.

ANSWER: C

Rationale:

A creatinine rise of up to 30–35% following RAAS inhibitor initiation is expected, acceptable, and associated with long-term renoprotection. This rise reflects the intended reduction in intraglomerular pressure: RAAS inhibition dilates the efferent arteriole, lowering glomerular filtration pressure and producing a predictable fall in GFR that is the pharmacological goal, not an adverse effect.

Option A: Option A is incorrect because a 28% creatinine rise does not indicate nephrotoxicity; the threshold for concern begins at rises approaching or exceeding 30–50%, particularly when accompanied by reversible contributing factors such as volume depletion or NSAID use.
Option B: Option B is incorrect because there is no evidence of volume depletion in this scenario, and adding a diuretic would be counterproductive.
Option D: Option D is incorrect because a 28% creatinine rise does not resolve spontaneously in 48 hours; the new creatinine level reflects the new hemodynamic steady state on RAAS inhibition.
Option E: Option E is incorrect because a 28% rise is within the acceptable range; the threshold for holding the drug begins at rises greater than 30–50% that are not explained by reversible causes.

2. Which of the following best describes the mechanism by which CKD causes hypertension?

A) Loss of nephron mass disrupts the normal pressure-natriuresis relationship, resetting the operating point of the kidney to defend a higher blood pressure in order to maintain sodium balance.
B) CKD causes primary hyperaldosteronism, which directly elevates blood pressure through excessive sodium retention independent of renin levels.
C) CKD impairs cardiac contractility, leading to a compensatory rise in peripheral vascular resistance that sustains hypertension.
D) Uremic toxins directly inhibit vascular smooth muscle relaxation by blocking potassium channels in the arteriolar wall.
E) CKD-induced anemia lowers systemic vascular resistance, triggering a baroreceptor-mediated increase in heart rate and blood pressure.

ANSWER: A

Rationale:

The fundamental mechanism by which CKD causes hypertension is disruption of the normal pressure-natriuresis relationship described by Guyton. Normally, rising blood pressure increases renal sodium excretion, correcting BP. As nephron mass is lost, the surviving nephrons must maintain sodium balance at a higher operating blood pressure — the pressure-natriuresis curve shifts rightward, and the kidney now defends an elevated BP. Additional mechanisms — RAAS activation, sympathetic stimulation, endothelial dysfunction, and volume expansion — amplify this primary defect.

Option B: Option B is incorrect because CKD does not cause primary hyperaldosteronism; aldosterone elevation in CKD is secondary to RAAS activation, not autonomous.
Option C: Option C is incorrect because CKD does not primarily impair cardiac contractility; hypertension in CKD is principally driven by volume overload and neurohumoral activation.
Option D: Option D is incorrect because uremic toxins impair endothelial nitric oxide (NO) production (causing vasoconstriction through loss of NO-mediated vasodilation), not through potassium channel blockade.
Option E: Option E is incorrect because while CKD-related anemia contributes to systolic hypertension through increased cardiac output, it is not the primary or fundamental mechanism of CKD-related hypertension.

3. According to KDIGO 2021 guidelines, which of the following patients with CKD should receive an ACE inhibitor or ARB as first-line antihypertensive therapy?

A) A patient with CKD stage 2 and UACR less than 30 mg/g who has never required antihypertensive therapy.
B) A patient with CKD stage 4 on hemodialysis with BP of 158/90 mmHg and no residual proteinuria.
C) A patient with CKD stage 3a with normal UACR whose BP is uncontrolled on amlodipine monotherapy.
D) A patient with CKD stage 3b and UACR of 320 mg/g whose BP is currently within target on lifestyle measures alone.
E) A patient with CKD stage 1 and UACR less than 30 mg/g with no cardiovascular risk factors.

ANSWER: D

Rationale:

KDIGO 2021 recommends ACE inhibitor or ARB as first-line antihypertensive therapy for all patients with CKD and albuminuria greater than 30 mg/g (Category A evidence), and strongly recommends RAAS inhibition for CKD with albuminuria greater than 300 mg/g regardless of BP level. The patient in option D has CKD stage 3b with a UACR of 320 mg/g — well above the 300 mg/g threshold — and therefore qualifies for RAAS inhibition based on proteinuria alone, even with BP currently at target, because of the antiproteinuric and renoprotective effects that are partially independent of systemic BP reduction.

Option A: Option A is incorrect because with UACR less than 30 mg/g, standard antihypertensive class selection applies and RAAS inhibition is not mandated.
Option B: Option B is incorrect because the dialysis patient has no residual proteinuria; while RAAS inhibitors may confer cardiovascular benefit in dialysis, they are not mandated on these grounds alone by KDIGO.
Option C: Option C is incorrect because with normal UACR, the addition of an ACE inhibitor or ARB would be appropriate for BP control but is not the recommended first line by KDIGO based on albuminuria indication.
Option E: Option E is incorrect because with UACR less than 30 mg/g and no additional risk factors, standard pharmacological treatment applies without RAAS inhibition mandate.

4. A patient with CKD stage 4 (eGFR 20 mL/min/1.73m2) and hypertension requires a diuretic for persistent volume overload. She is currently on telmisartan and amlodipine. Which diuretic class is most appropriate at this stage of CKD?

A) Hydrochlorothiazide (HCTZ) 25 mg daily; thiazides are the preferred first-line diuretic across all CKD stages.
B) Furosemide 40 mg twice daily; loop diuretics are the preferred diuretic at eGFR below 30 mL/min/1.73m2 because thiazide efficacy is substantially reduced at this GFR.
C) Spironolactone 25 mg daily; mineralocorticoid receptor antagonists (MRAs) provide both diuresis and renoprotection in advanced CKD.
D) Metolazone 5 mg daily; this thiazide-like agent retains efficacy at eGFR below 30 better than any loop diuretic.
E) Amiloride 5 mg daily; potassium-sparing diuretics are preferred in advanced CKD to prevent potassium wasting.

ANSWER: B

Rationale:

At eGFR below 30 mL/min/1.73m2, thiazide and thiazide-like diuretics lose most of their natriuretic efficacy because they depend on active tubular secretion to reach their site of action (the distal convoluted tubule), and reduced nephron mass and impaired tubular secretion limit this access. Loop diuretics act on the thick ascending limb of the loop of Henle, a site with far greater natriuretic capacity, and retain meaningful efficacy even at very low eGFR when adequate doses are used. Furosemide or torsemide (with superior oral bioavailability) are the appropriate choices.

Option A: Option A is incorrect because HCTZ efficacy is substantially reduced at eGFR below 30; it is not a reliable diuretic at CKD stage 4.
Option C: Option C is incorrect because spironolactone in stage 4 CKD with concurrent telmisartan carries a high risk of dangerous hyperkalemia; it is not appropriate as routine first-line diuretic therapy in this setting.
Option D: Option D is incorrect because metolazone, while occasionally used as an adjunct to loop diuretics in diuretic-resistant states, is not more effective than loop diuretics at eGFR below 30 and is not a first-line agent here.
Option E: Option E is incorrect because amiloride is a potassium-sparing agent that should be avoided in stage 4 CKD due to significant hyperkalemia risk, particularly with concurrent RAAS inhibition.

5. The DAPA-CKD trial established an important advance in the management of CKD. Which of the following best summarizes the landmark finding of this trial?

A) Dapagliflozin reduced the risk of doubling of serum creatinine and ESRD in patients with type 2 diabetic nephropathy, but only when used in combination with an ACE inhibitor.
B) Dapagliflozin significantly reduced BP by more than 15 mmHg systolic in patients with CKD, making it an effective antihypertensive agent independent of its renal effects.
C) Dapagliflozin reduced the primary renal composite endpoint in CKD patients regardless of diabetes status, at eGFR as low as 25 mL/min/1.73m2, with a 39% relative risk reduction.
D) Dapagliflozin eliminated the need for RAAS inhibition in patients with CKD and significant albuminuria, as SGLT2 inhibition provides equivalent renoprotection through tubuloglomerular feedback.
E) Dapagliflozin demonstrated a 39% reduction in the primary renal composite endpoint in patients with CKD and significant albuminuria, with or without type 2 diabetes, at eGFR 25–75 mL/min/1.73m2, on background RAAS inhibition.

ANSWER: E

Rationale:

The DAPA-CKD trial (2020) enrolled patients with CKD (eGFR 25–75 mL/min/1.73m2 and UACR ≥ 200 mg/g) on background RAAS inhibition, and demonstrated a 39% reduction in the primary composite endpoint — sustained ≥50% eGFR decline, ESRD, or renal or cardiovascular death — with dapagliflozin 10 mg daily compared to placebo. Critically, this benefit was observed in patients with and without type 2 diabetes, establishing SGLT2 inhibitor renoprotection as a class effect that is not dependent on glucose-lowering. Option C is accurate in describing the landmark finding but incorrectly states it was "only when used in combination with an ACE inhibitor," which was not a study requirement — option E more precisely and completely captures the trial design and result.

Option A: Option A is incorrect because DAPA-CKD included patients without diabetes and the benefit was not restricted to those already on an ACE inhibitor.
Option B: Option B is incorrect because the antihypertensive effect of SGLT2 inhibitors is modest (approximately 3–5 mmHg systolic); a 15 mmHg reduction is not a characteristic of this class.
Option D: Option D is incorrect because dapagliflozin does not eliminate the need for RAAS inhibition; the two classes have complementary, mechanistically distinct renoprotective effects and are used in combination.

6. A patient with CKD stage 3b is on losartan and amlodipine. His potassium rises to 5.8 mEq/L. After dietary counseling and potassium restriction, the potassium remains at 5.6 mEq/L. Which of the following is an appropriate strategy to allow continuation of losartan?

A) Add spironolactone 12.5 mg daily to counteract the RAAS-induced potassium retention through competitive receptor blockade.
B) Increase amlodipine to 10 mg daily; higher CCB doses reduce serum potassium through enhanced kaliuresis.
C) Add a potassium binder such as patiromer or sodium zirconium cyclosilicate to lower serum potassium and allow continuation of RAAS inhibition.
D) Discontinue losartan and switch to a CCB-only regimen; potassium of 5.6 mEq/L is an absolute contraindication to continued RAAS inhibition.
E) Add a loop diuretic; the kaliuretic effect will sufficiently reduce potassium to allow continuation of losartan without additional interventions.

ANSWER: C

Rationale:

Potassium binders — patiromer and sodium zirconium cyclosilicate (SZC) — are specifically indicated to enable continuation of RAAS inhibition in patients with CKD-related hyperkalemia. These agents bind potassium in the gastrointestinal tract, reducing absorption and lowering serum potassium, thereby allowing RAAS inhibitors to be maintained at therapeutic doses. This is an increasingly important strategy given the critical renoprotective benefit of RAAS inhibition in CKD with albuminuria.

Option A: Option A is incorrect because adding spironolactone in a patient who is already hyperkalemic on an ARB would substantially worsen hyperkalemia by adding a second potassium-retaining agent; this combination is contraindicated in this setting.
Option B: Option B is incorrect because amlodipine has no kaliuretic effect; CCBs do not influence potassium handling.
Option D: Option D is incorrect because a potassium of 5.6 mEq/L, while requiring action, is not an absolute contraindication to continued RAAS inhibition; the threshold for mandatory discontinuation is generally greater than 5.5–6.0 mEq/L persistently despite management, and potassium binder strategies should be attempted first.
Option E: Option E is incorrect because adding a loop diuretic may produce some kaliuresis but is not sufficient as the sole strategy for persistent hyperkalemia at this level, and is not the most direct or guideline-supported intervention for enabling RAAS inhibitor continuation.

7. Which of the following ACE inhibitors is preferred in CKD stage 4 due to its dual renal and hepatic elimination pathway?

A) Fosinopril, which undergoes approximately equal hepatic and renal elimination, providing more predictable drug levels as eGFR declines below 30 mL/min/1.73m2.
B) Lisinopril, which is exclusively renally eliminated and therefore provides the most predictable dosing in CKD due to its simple pharmacokinetic profile.
C) Captopril, which is renally eliminated and can be given in small frequent doses to minimize accumulation in CKD stage 4.
D) Enalapril, which is converted to enalaprilat hepatically and therefore accumulates minimally in CKD regardless of the degree of renal impairment.
E) Benazepril, which is excreted entirely in bile and therefore requires no dose adjustment across any stage of CKD.

ANSWER: A

Rationale:

Fosinopril is the ACE inhibitor with the most balanced dual elimination — approximately 50% renal and 50% hepatic — making it the preferred ACEi in advanced CKD, including stage 4, because declining GFR does not produce the same degree of drug accumulation as with predominantly renally eliminated agents. As renal elimination decreases, hepatic elimination compensates, maintaining more predictable drug levels.

Option B: Option B is incorrect because lisinopril is almost exclusively renally eliminated and accumulates significantly in CKD, requiring dose reduction and increasing the risk of first-dose hypotension and bradykinin-related adverse effects; it is therefore less preferred in advanced CKD, not more.
Option C: Option C is incorrect because captopril is also substantially renally eliminated and requires dose reduction in CKD; it is not preferred in stage 4 CKD and its short half-life makes three-times-daily dosing burdensome.
Option D: Option D is incorrect because while enalapril's conversion to enalaprilat occurs hepatically, enalaprilat itself is renally eliminated and accumulates in advanced CKD, requiring dose reduction.
Option E: Option E is incorrect because benazepril has dual elimination (approximately 85% renal, 15% hepatic) but is not excreted entirely in bile; the description is inaccurate.

8. The VA NEPHRON-D trial is relevant to the management of hypertension in CKD. Which of the following accurately describes the key finding of this trial?

A) Dual RAAS blockade with an ACE inhibitor plus an ARB significantly reduced the risk of ESRD in type 2 diabetic nephropathy compared to either agent alone.
B) Combination ACEi plus ARB therapy reduced all-cause mortality in CKD patients with significant proteinuria, supporting its use in high-risk patients.
C) Dual RAAS blockade with ACEi plus direct renin inhibitor (aliskiren) significantly reduced proteinuria without excess harm in non-diabetic CKD.
D) Combination ACE inhibitor plus ARB therapy produced excess acute kidney injury and hyperkalemia without a significant reduction in renal endpoints, establishing that dual RAAS blockade is contraindicated in CKD.
E) Adding an ARB to an ACE inhibitor in type 1 diabetic nephropathy produced a 30% reduction in ESRD at the cost of significantly increased hyperkalemia, creating a guideline-endorsed benefit-risk exception for high-proteinuria patients.

ANSWER: D

Rationale:

The VA NEPHRON-D trial randomized patients with type 2 diabetic nephropathy to losartan plus lisinopril versus losartan plus placebo. The trial was stopped early due to significantly higher rates of acute kidney injury and hyperkalemia in the combination group without any meaningful reduction in renal endpoints. This definitively established that dual RAAS blockade with an ACE inhibitor plus ARB is contraindicated in CKD and should not be used.

Option A: Option A is incorrect because VA NEPHRON-D showed the opposite: no significant reduction in renal endpoints with dual blockade.
Option B: Option B is incorrect because the trial was stopped early for harm (excess AKI and hyperkalemia) and showed no mortality benefit from combination therapy.
Option C: Option C is incorrect because VA NEPHRON-D studied ACEi plus ARB, not ACEi plus aliskiren; the ALTITUDE trial evaluated aliskiren and also showed harm with dual RAAS blockade in diabetic nephropathy.
Option E: Option E is incorrect because no such guideline-endorsed exception exists for ACEi plus ARB in CKD; this combination is explicitly contraindicated by KDIGO 2021 regardless of proteinuria level.

9. A patient with CKD stage 3b and hypertension on lisinopril and amlodipine develops an acute gastrointestinal illness with vomiting and poor oral intake for 48 hours. What is the most appropriate advice regarding his medications during this illness?

A) Continue all medications as usual; withholding antihypertensives during illness risks rebound hypertension that is more harmful than the illness itself.
B) Hold both the lisinopril and any diuretics for the duration of the acute illness to prevent AKI from RAAS inhibition and volume depletion in the setting of reduced oral intake.
C) Hold lisinopril but continue amlodipine; CCBs are safe during acute illness because they do not affect renal perfusion pressure.
D) Double the lisinopril dose to counteract the rise in renin activity that accompanies volume depletion during acute illness.
E) Switch lisinopril to a shorter-acting ACE inhibitor temporarily to allow rapid dose adjustment based on daily renal function measurements.

ANSWER: B

Rationale:

Patients on RAAS inhibitors and diuretics should be advised to hold these medications during acute illness associated with significant volume depletion — vomiting, diarrhea, or fever with poor oral intake. In the setting of reduced effective circulating volume, RAAS inhibition reduces renal perfusion pressure further by dilating the efferent arteriole, and diuretics exacerbate volume depletion, together creating a high-risk situation for acute kidney injury (AKI). This "sick day" guidance is an important patient safety intervention in CKD management. Amlodipine (a CCB) does not affect renal perfusion pressure or tubular function and may generally be continued, but the priority is holding RAAS inhibitors and diuretics. Option C is partially correct regarding amlodipine safety but incorrect in its reasoning, as the question asks specifically about the most appropriate advice for the full medication regimen.

Option A: Option A is incorrect because the risk of AKI from continuing RAAS inhibition during volume depletion is real and clinically significant; rebound hypertension over 48–72 hours of illness is a much smaller risk than AKI on a background of CKD.
Option D: Option D is incorrect because doubling lisinopril during volume depletion would markedly increase the risk of AKI and hypotension.
Option E: Option E is incorrect because switching to a shorter-acting agent is not a guideline-supported strategy and introduces unnecessary medication complexity during an acute illness.

10. Which of the following best describes the mechanism by which elevated intraglomerular pressure drives progressive nephron loss in CKD?

A) High intraglomerular pressure causes direct compression of the glomerular capillary basement membrane, reducing filtration surface area and permanently impairing GFR.
B) Elevated glomerular pressure activates aldosterone receptors on mesangial cells, stimulating proliferation and progressive glomerulosclerosis.
C) High intraglomerular pressure causes afferent arteriolar vasospasm, reducing GFR acutely and chronically through ischemia of the glomerular tuft.
D) Elevated intraglomerular pressure accelerates podocyte loss through mechanical stretch injury, but the resulting proteinuria has no independent nephrotoxic effect.
E) Elevated intraglomerular pressure drives proteinuria, and filtered proteins activate tubular cells, promoting inflammation, interstitial fibrosis, and further nephron loss through a self-amplifying cycle.

ANSWER: E

Rationale:

The pressure-proteinuria-fibrosis axis is the central mechanism of progressive nephron loss in CKD. Elevated intraglomerular pressure increases glomerular permeability and drives the filtration of proteins that would normally be excluded. These filtered proteins are directly nephrotoxic: albumin carries fatty acids that damage proximal tubular cells, protein casts obstruct tubular lumina, complement activation within tubular fluid drives interstitial injury, and filtered proteins activate tubular epithelial cells to release chemokines and cytokines that recruit macrophages and drive interstitial inflammation and fibrosis. This fibrosis causes further nephron loss, worsening systemic hypertension, and perpetuates the cycle.

Option A: Option A is incorrect because intraglomerular hypertension does not cause mechanical compression of the basement membrane in this way; it causes increased wall tension and permeability.
Option B: Option B is incorrect because aldosterone acts primarily through mineralocorticoid receptors on tubular cells and mediates fibrosis via TGF-beta and oxidative stress pathways, not through mesangial cell aldosterone receptors.
Option C: Option C is incorrect because elevated intraglomerular pressure does not cause afferent arteriolar vasospasm; afferent vasospasm would actually reduce intraglomerular pressure, not elevate it.
Option D: Option D is incorrect because proteinuria has well-established independent nephrotoxic effects; the statement that it has no independent nephrotoxic effect is factually wrong.

11. The CLICK trial evaluated diuretic therapy in advanced CKD. Which of the following best describes the clinical significance of this trial?

A) The CLICK trial demonstrated that furosemide is superior to chlorthalidone in CKD stage 3–4, establishing loop diuretics as the first-line diuretic in all patients with eGFR below 60 mL/min/1.73m2.
B) The CLICK trial showed that indapamide reduces proteinuria more effectively than chlorthalidone in CKD stage 3, supporting indapamide as the preferred thiazide-like diuretic for renoprotective therapy.
C) The CLICK trial demonstrated that chlorthalidone 12.5–25 mg significantly reduced 24-hour ambulatory systolic BP by approximately 11 mmHg versus placebo in patients with CKD stage 3–4 on optimal background therapy, including RAAS inhibitors.
D) The CLICK trial found that chlorthalidone caused excessive electrolyte disturbances in CKD stage 4 patients, leading to a recommendation against thiazide use below eGFR 30 mL/min/1.73m2.
E) The CLICK trial established that combining chlorthalidone with a loop diuretic in CKD stage 3–4 reduces the risk of ESRD by 35% compared to loop diuretic monotherapy.

ANSWER: C

Rationale:

The CLICK trial (Chlorthalidone in Chronic Kidney Disease, 2021) randomized patients with CKD stage 3–4 (eGFR 15–30 mL/min/1.73m2 in the primary cohort) who had uncontrolled hypertension on background RAAS inhibition to chlorthalidone 12.5–25 mg daily versus placebo. The primary outcome — change in 24-hour ambulatory systolic BP at 12 weeks — showed an 11 mmHg reduction with chlorthalidone versus placebo. This was a clinically important finding because it demonstrated that thiazide-like diuretics retain meaningful antihypertensive efficacy even in stage 3–4 CKD when used at appropriate doses on top of existing RAAS-based regimens.

Option A: Option A is incorrect because CLICK did not compare chlorthalidone to furosemide; it compared chlorthalidone to placebo.
Option B: Option B is incorrect because the CLICK trial did not study indapamide; it specifically evaluated chlorthalidone.
Option D: Option D is incorrect because the CLICK trial did not recommend against thiazide use in CKD; rather, it supported chlorthalidone's antihypertensive utility in this population, though monitoring of electrolytes was required.
Option E: Option E is incorrect because the CLICK trial was a short-term hemodynamic/BP study, not a hard renal endpoint trial; it did not report ESRD outcomes.

12. Which of the following statements about calcium channel blockers (CCBs) in CKD is correct?

A) Amlodipine requires no dose adjustment across any stage of CKD, is highly effective, and has no adverse renal hemodynamic effects, making it a preferred add-on agent at all CKD stages.
B) Amlodipine reduces intraglomerular pressure by dilating the efferent arteriole, providing renoprotective benefit similar to that of RAAS inhibitors.
C) Non-dihydropyridine CCBs (verapamil, diltiazem) are preferred over amlodipine in CKD because they reduce proteinuria more effectively through direct glomerular effects.
D) CCBs are contraindicated in CKD stage 4 because they dilate the afferent arteriole, increasing intraglomerular pressure and accelerating nephron loss.
E) Amlodipine accumulates in CKD stage 4 due to reduced hepatic metabolism, requiring dose reduction to 2.5 mg daily to prevent peripheral edema and hypotension.

ANSWER: A

Rationale:

Amlodipine is a preferred antihypertensive agent across all stages of CKD because it requires no dose adjustment regardless of eGFR (it is hepatically metabolized with no renal dose dependency), is highly effective as an antihypertensive in this population, and has no adverse renal hemodynamic effects. It is the preferred add-on agent in combination with RAAS inhibitors in CKD, supported by the ACCOMPLISH paradigm (ACEi plus CCB superior to ACEi plus diuretic in high-cardiovascular-risk patients including those with CKD).

Option B: Option B is incorrect because amlodipine does not dilate the efferent arteriole; RAAS inhibitors dilate the efferent arteriole to reduce intraglomerular pressure. Amlodipine dilates the afferent arteriole (systemic arterioles in general), which can slightly increase intraglomerular pressure, which is why RAAS inhibitors are preferred for renoprotection.
Option C: Option C is incorrect because while non-DHP CCBs (verapamil, diltiazem) do have modest antiproteinuric effects, they are not preferred over amlodipine in CKD, particularly given their added burdens (constipation, drug interactions, negative inotropy).
Option D: Option D is incorrect because CCBs are not contraindicated in CKD at any stage; the afferent dilation effect does not clinically accelerate nephron loss in the context of background RAAS inhibition.
Option E: Option E is incorrect because amlodipine is hepatically metabolized and does not require dose reduction in CKD; peripheral edema is a dose-dependent side effect but is not prevented by dose reduction in CKD specifically.

13. What is the current ACC/AHA 2017 recommended blood pressure target for patients with CKD regardless of albuminuria status or diabetes?

A) Less than 140/90 mmHg; more aggressive targets have not shown benefit and increase the risk of AKI in CKD.
B) Less than 125/75 mmHg; aggressive BP control is required to halt the pressure-proteinuria-fibrosis axis in all CKD patients.
C) Less than 150/90 mmHg in patients older than 60 years with CKD, consistent with elderly hypertension guidelines.
D) Less than 130/80 mmHg for all patients with CKD, with or without albuminuria, with or without diabetes.
E) Less than 120/80 mmHg, consistent with the SPRINT intensive target, which enrolled predominantly CKD patients.

ANSWER: D

Rationale:

The ACC/AHA 2017 hypertension guideline recommends a BP target of less than 130/80 mmHg for all patients with CKD, regardless of albuminuria status and regardless of the presence or absence of diabetes. This unified target simplifies the clinical approach and reflects the evidence that lower BP targets are associated with better renal and cardiovascular outcomes across the CKD spectrum.

Option A: Option A is incorrect because the 2017 ACC/AHA guideline explicitly lowered the target to less than 130/80 mmHg for CKD patients, replacing the older 140/90 mmHg target.
Option B: Option B is incorrect because a target of less than 125/75 mmHg is not recommended by current major guidelines; it is not supported by the evidence base and risks excessive diastolic BP reduction (J-curve concerns).
Option C: Option C is incorrect because the ACC/AHA 2017 guideline does not stratify the CKD BP target by age in the way described; the 130/80 mmHg target applies broadly, though clinical judgment about tolerability and frailty is always important.
Option E: Option E is incorrect because while KDIGO 2021 does recommend a systolic target of less than 120 mmHg based on standardized automated BP measurement, the ACC/AHA 2017 guideline target is less than 130/80 mmHg, and SPRINT measurement methodology (automated unattended) differs from standard attended clinical measurement.

14. A patient with CKD stage 3b begins losartan 50 mg daily. At 3-month follow-up, his UACR has fallen from 520 mg/g to 310 mg/g (a 40% reduction) and his BP is well controlled at 124/76 mmHg. How should this antiproteinuric response be interpreted and managed?

A) The UACR reduction is satisfactory; no further dose titration of losartan is needed and the patient can be seen at 12-month intervals.
B) A fall in UACR of greater than 30% from baseline at 3 months confirms a favorable antiproteinuric response that predicts long-term renoprotection; the dose should be titrated to maximize proteinuria reduction within tolerability limits.
C) The UACR reduction is a nonspecific finding that reflects normal disease fluctuation; it should not influence drug dosing decisions.
D) A UACR fall of 40% is insufficient; the target is complete elimination of proteinuria (UACR < 30 mg/g) within 3 months, requiring immediate dose doubling.
E) The UACR reduction confirms renoprotection is established; losartan should now be replaced with an SGLT2 inhibitor to prevent the hyperkalemia that will develop with continued ARB use.

ANSWER: B

Rationale:

A fall in proteinuria of greater than 30% from baseline following RAAS inhibitor initiation is a validated surrogate for long-term renoprotection — it predicts slowing of CKD progression independently of systemic BP changes. The antiproteinuric response at 3 months should be used to guide dose titration: the goal is to maximize proteinuria reduction within tolerability limits (i.e., titrate to the highest dose that does not produce dangerous hyperkalemia, excessive creatinine rise, or hypotension). This patient's 40% UACR reduction is excellent and confirms a favorable response.

Option A: Option A is incorrect because seeing a well-responding patient only at 12-month intervals is insufficiently frequent for CKD stage 3b on RAAS inhibition; monitoring at 3-month intervals is the minimum standard, and dose optimization should continue.
Option C: Option C is incorrect because the antiproteinuric response to RAAS inhibitors is well-established as a clinical marker of renoprotection, not a nonspecific fluctuation.
Option D: Option D is incorrect because complete elimination of proteinuria within 3 months is not the expected or required target; the 30% reduction threshold predicts long-term protection and is clinically meaningful without requiring normalization.
Option E: Option E is incorrect because successful RAAS inhibitor therapy is not replaced by SGLT2 inhibitors; the two classes are used together as additive renoprotective strategies.

15. A patient with CKD stage 4 requires a beta-blocker for heart failure with reduced ejection fraction (HFrEF). Which beta-blocker is most appropriate in this setting and why?

A) Atenolol, because its water solubility ensures it is renally eliminated and therefore the drug level can be predicted from eGFR alone.
B) Metoprolol succinate, because it is entirely renally eliminated and requires a fixed dose reduction of 50% at eGFR below 30 mL/min/1.73m2.
C) Bisoprolol is not recommended in CKD stage 4 due to accumulation causing excessive bradycardia; carvedilol is preferred for its hepatic elimination.
D) Propranolol is preferred in CKD stage 4 because its lipid solubility prevents renal accumulation and provides more consistent beta-blockade than water-soluble agents.
E) Bisoprolol is preferred because its dual renal and hepatic elimination (approximately 50%/50%) provides more predictable drug levels in CKD stage 4 than predominantly renally eliminated agents such as atenolol.

ANSWER: E

Rationale:

Bisoprolol undergoes approximately equal renal and hepatic elimination (roughly 50%/50%), which makes it more predictable in advanced CKD than predominantly renally eliminated agents. As renal function declines, the hepatic elimination pathway compensates, preventing the degree of accumulation seen with atenolol. Among the HFrEF-indicated beta-blockers (bisoprolol, carvedilol, metoprolol succinate), bisoprolol is the preferred choice in CKD stage 4. Carvedilol and metoprolol are hepatically metabolized and are also reasonable options, but bisoprolol's established place in CKD management and its dual elimination make it the most clearly appropriate answer here.

Option A: Option A is incorrect because atenolol's renal elimination in CKD stage 4 is precisely the problem, not the advantage: it accumulates to unpredictable and potentially toxic levels as eGFR declines, and is therefore less preferred.
Option B: Option B is incorrect because metoprolol succinate is hepatically metabolized (not renally eliminated) and does not require a fixed 50% dose reduction in CKD; it is a reasonable option but the statement is factually inaccurate.
Option C: Option C is incorrect because bisoprolol is recommended and used in CKD stage 4; it does not accumulate to dangerous degrees due to its dual elimination, and this statement mischaracterizes the pharmacology.
Option D: Option D is incorrect because propranolol is hepatically metabolized (lipid solubility relates to CNS penetration, not renal accumulation) and is not a first-line HFrEF beta-blocker; the statement conflates lipid solubility with renal elimination in a misleading way.

16. Which of the following is an absolute contraindication to continued ACE inhibitor or ARB therapy in a patient with CKD?

A) A creatinine rise of 25% above baseline at 4 weeks following ACE inhibitor initiation in a patient who is clinically stable and well-hydrated.
B) Persistent UACR of 450 mg/g despite 6 months of maximum-dose RAAS inhibition, indicating lack of antiproteinuric response.
C) Confirmed bilateral renal artery stenosis, in which RAAS inhibition removes the angiotensin II-driven efferent constriction that maintains glomerular filtration across the stenosed vessels.
D) A potassium of 5.3 mEq/L at 2-week follow-up after ACE inhibitor initiation, with the patient otherwise asymptomatic and on a normal diet.
E) An eGFR of 18 mL/min/1.73m2 with stable creatinine and well-controlled potassium on an existing ACE inhibitor regimen.

ANSWER: C

Rationale:

Bilateral renal artery stenosis is an absolute contraindication to RAAS inhibitor use. In this condition, glomerular filtration pressure depends critically on angiotensin II-mediated efferent arteriolar constriction to maintain the pressure gradient across the stenosed afferent vessels. RAAS inhibition eliminates this compensatory efferent constriction, causing a precipitous fall in GFR and potentially severe acute kidney injury. The same principle applies to stenosis of a solitary functioning kidney.

Option A: Option A is incorrect because a 25% creatinine rise is within the acceptable range (up to 30–35%) and reflects expected hemodynamic response to RAAS inhibition; drug continuation with close monitoring is appropriate.
Option B: Option B is incorrect because an inadequate antiproteinuric response is not an absolute contraindication; it may prompt addition of complementary agents (SGLT2 inhibitors, finerenone) or reassessment of adherence and dietary sodium intake, but RAAS inhibition is maintained.
Option D: Option D is incorrect because a potassium of 5.3 mEq/L at 2 weeks, while above the upper limit of normal, does not require drug discontinuation; the threshold for concern begins at 5.5 mEq/L, and dietary counseling with close monitoring is appropriate.
Option E: Option E is incorrect because an eGFR of 18 mL/min/1.73m2 with stable parameters is not an absolute contraindication to continuation of RAAS inhibitors already established; the benefit-risk calculation favors continuation for cardiovascular and residual renal protection.